Cartesian Therapeutics Inc.
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
- Ticker
- RNAC
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Carsten Brunn Ph.D.
- Headquarters
- 7495 New Horizon Way, Frederick, MD, United States, 21703
- Employees
- 75
- Website
- cartesiantherapeutics.com
Metrics
Analyst Insights & forecasts
Based on information from 7 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$2.71 | -$0.95 | $0.46 |
| Expected | -$0.79 | -$0.70 | -$0.83 |
| Surprise | -242.59% | -35.71% | 155.42% |
| Missed | Missed | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $13.7M | $-11.5M | -183.62% |
| Profit margin | ∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Cartesian Therapeutics Inc. share?
Cartesian Therapeutics Inc. shares are currently traded for undefined per share.
02How many shares does Cartesian Therapeutics Inc. have?
Cartesian Therapeutics Inc. currently has 30.5M shares.
03Does Cartesian Therapeutics Inc. pay dividends?
No, Cartesian Therapeutics Inc. doesn't pay dividends.
04What is Cartesian Therapeutics Inc. 52 week high?
Cartesian Therapeutics Inc. 52 week high is $11.00.
05What is Cartesian Therapeutics Inc. 52 week low?
Cartesian Therapeutics Inc. 52 week low is $5.60.
06What is the 200-day moving average of Cartesian Therapeutics Inc.?
Cartesian Therapeutics Inc. 200-day moving average is $7.62.
07Who is Cartesian Therapeutics Inc. CEO?
The CEO of Cartesian Therapeutics Inc. is Dr. Carsten Brunn Ph.D..
08How many employees Cartesian Therapeutics Inc. has?
Cartesian Therapeutics Inc. has 75 employees.
09What is the market cap of Cartesian Therapeutics Inc.?
The market cap of Cartesian Therapeutics Inc. is $192M.
10What is the P/E of Cartesian Therapeutics Inc.?
The current P/E of Cartesian Therapeutics Inc. is null.
11What is the EPS of Cartesian Therapeutics Inc.?
The EPS of Cartesian Therapeutics Inc. is -$4.78.
12What is the PEG Ratio of Cartesian Therapeutics Inc.?
The PEG Ratio of Cartesian Therapeutics Inc. is 0.
13What do analysts say about Cartesian Therapeutics Inc.?
According to the analysts Cartesian Therapeutics Inc. is considered a buy.
